Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting

Cytokine and Growth Factor Reviews

Volumn 36, Issue , 2017, Pages 67-77

  Sistigu, Antonella ^a,b   Di Modugno, Francesca ^a   Manic, Gwenola ^c   Nisticò, Paola ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

CSC; EMT; Tumor immunoediting; Tumor microenvironment

Indexed keywords

CYTOKINE; DOXORUBICIN; FLUOROURACIL; GEMCITABINE;

BIOMECHANICS; CANCER ASSOCIATED FIBROBLAST; CANCER IMMUNOEDITING; CANCER RESISTANCE; CANCER STEM CELL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HYPOXIA; IMMUNOCOMPETENT CELL; INFLAMMATION; NONHUMAN; PH; PLASTICITY; PRIORITY JOURNAL; REVIEW; STROMA CELL; TUMOR CELL; TUMOR IMMUNITY; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; CELL TRANSFORMATION; DISEASE EXACERBATION; EXTRACELLULAR MATRIX; GENETICS; IMMUNOLOGY; MOUSE; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMANS; INFLAMMATION; MICE; NEOPLASMS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 85020173566     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2017.05.008     Document Type: Review

References (128)

1. Duval, M., Atlas d'Embryologie. 1879, Masson, Paris.
2. Greenburg, G., Hay, E.D., Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. J. Cell Biol. 95 (1982), 333–339.
3. Thiery, J.P., Sleeman, J.P., Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7 (2006), 131–142.
4. Yan, C., Grimm, W.A., Garner, W.L., Qin, L., Travis, T., Tan, N., et al. Epithelial to mesenchymal transition in human skin wound healing is induced by tumor necrosis factor-alpha through bone morphogenic protein-2. Am. J. Pathol. 176 (2010), 2247–2258.
5. Weber, C.E., Li, N.Y., Wai, P.Y., Kuo, P.C., Epithelial-mesenchymal transition, TGF-beta, and osteopontin in wound healing and tissue remodeling after injury. J. Burn Care Res. 33 (2012), 311–318.
6. Radisky, D.C., Kenny, P.A., Bissell, M.J., Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT. J. Cell. Biochem. 101 (2007), 830–839.
7. Acloque, H., Thiery, J.P., Nieto, M.A., The physiology and pathology of the EMT. Meeting on the epithelial-mesenchymal transition. EMBO Rep. 9 (2008), 322–326.
8. Nieto, M.A., Epithelial plasticity: a common theme in embryonic and cancer cells. Science, 342, 2013, 1234850.
9. Palena, C., Hamilton, D.H., Fernando, R.I., Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. Future Oncol. 8 (2012), 713–722.
10. Liu, R.Y., Zeng, Y., Lei, Z., Wang, L., Yang, H., Liu, Z., et al. JAK/STAT3 signaling is required for TGF-beta-induced epithelial-mesenchymal transition in lung cancer cells. Int. J. Oncol. 44 (2014), 1643–1651.
11. Wu, Y., Deng, J., Rychahou, P.G., Qiu, S., Evers, B.M., Zhou, B.P., Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 15 (2009), 416–428.
12. Gonzalez, D.M., Medici, D., Signaling mechanisms of the epithelial-mesenchymal transition. Sci. Signal., 7, 2014, re8.
13. Nistico, P., Bissell, M.J., Radisky, D.C., Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. Cold Spring Harb. Perspect. Biol., 2012, 2012.
14. Marcucci, F., Bellone, M., Caserta, C.A., Corti, A., Pushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications and alternative roads. Int. J. Cancer 135 (2014), 1265–1276.
15. Venables, J.P., Klinck, R., Koh, C., Gervais-Bird, J., Bramard, A., Inkel, L., et al. Cancer-associated regulation of alternative splicing. Nat. Struct. Mol. Biol. 16 (2009), 670–676.
16. Warzecha, C.C., Carstens, R.P., Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT). Semin. Cancer Biol. 22 (2012), 417–427.
17. Horiguchi, K., Sakamoto, K., Koinuma, D., Semba, K., Inoue, A., Inoue, S., et al. TGF-beta drives epithelial-mesenchymal transition through deltaEF1-mediated downregulation of ESRP. Oncogene 31 (2012), 3190–3201.
18. Shapiro, I.M., Cheng, A.W., Flytzanis, N.C., Balsamo, M., Condeelis, J.S., Oktay, M.H., et al. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet., 7, 2011, e1002218.
19. Di Modugno, F., Iapicca, P., Boudreau, A., Mottolese, M., Terrenato, I., Perracchio, L., et al. Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 19280–19285.
20. Bria, E., Di Modugno, F., Sperduti, I., Iapicca, P., Visca, P., Alessandrini, G., et al. Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer. Oncotarget 5 (2014), 11054–11063.
21. Melchionna, R., Iapicca, P., Di Modugno, F., Trono, P., Sperduti, I., Fassan, M., et al. The pattern of hMENA isoforms is regulated by TGF-beta1 in pancreatic cancer and may predict patient outcome. Oncoimmunology, 5, 2016, e1221556.
22. Hao, J., Zhang, Y., Deng, M., Ye, R., Zhao, S., Wang, Y., et al. MicroRNA control of epithelial-mesenchymal transition in cancer stem cells. Int. J. Cancer 135 (2014), 1019–1027.
23. Gregory, P.A., Bracken, C.P., Smith, E., Bert, A.G., Wright, J.A., Roslan, S., et al. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol. Biol. Cell 22 (2011), 1686–1698.
24. Rateitschak, K., Kaderali, L., Wolkenhauer, O., Jaster, R., Autocrine TGF-beta/ZEB/microRNA-200 signal transduction drives epithelial-mesenchymal transition: kinetic models predict minimal drug dose to inhibit metastasis. Cell. Signal. 28 (2016), 861–870.
25. Siemens, H., Jackstadt, R., Hunten, S., Kaller, M., Menssen, A., Gotz, U., et al. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 10 (2011), 4256–4271.
26. Mantovani, A., Allavena, P., Sica, A., Balkwill, F., Cancer-related inflammation. Nature 454 (2008), 436–444.
27. Jing, Y., Han, Z., Zhang, S., Liu, Y., Wei, L., Epithelial-Mesenchymal Transition in tumor microenvironment. Cell Biosci., 1, 2011, 29.
28. Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., Allavena, P., Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol., 2017.
29. Bonde, A.K., Tischler, V., Kumar, S., Soltermann, A., Schwendener, R.A., Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. BMC Cancer, 12, 2012, 35.
30. Bates, R.C., Mercurio, A.M., Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol. Biol. Cell 14 (2003), 1790–1800.
31. Condeelis, J., Pollard, J.W., Macrophages obligate partners for tumor cell migration, invasion, and metastasis. Cell 124 (2006), 263–266.
32. Standiford, T.J., Kuick, R., Bhan, U., Chen, J., Newstead, M., Keshamouni, V.G., TGF-beta-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth. Oncogene 30 (2011), 2475–2484.
33. Freisinger, C.M., Huttenlocher, A., Live imaging and gene expression analysis in zebrafish identifies a link between neutrophils and epithelial to mesenchymal transition. PLoS One, 9, 2014, e112183.
34. Toh, B., Wang, X., Keeble, J., Sim, W.J., Khoo, K., Wong, W.C., et al. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol., 9, 2011, e1001162.
35. Labelle, M., Begum, S., Hynes, R.O., Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20 (2011), 576–590.
36. Massague, J., TGFbeta in cancer. Cell 134 (2008), 215–230.
37. Moses, H.L., Roberts, A.B., Derynck, R., The discovery and early days of TGF-beta: a historical perspective. Cold Spring Harb. Perspect. Biol., 2016, 2016.
38. Lamouille, S., Xu, J., Derynck, R., Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15 (2014), 178–196.
39. Derynck, R., Muthusamy, B.P., Saeteurn, K.Y., Signaling pathway cooperation in TGF-beta-induced epithelial-mesenchymal transition. Curr. Opin. Cell Biol. 31 (2014), 56–66.
40. Yang, L., Pang, Y., Moses, H.L., TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 31 (2010), 220–227.
41. Hunter, C.A., Jones, S.A., IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16 (2015), 448–457.
42. Sullivan, N.J., Sasser, A.K., Axel, A.E., Vesuna, F., Raman, V., Ramirez, N., et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 28 (2009), 2940–2947.
43. Rokavec, M., Oner, M.G., Li, H., Jackstadt, R., Jiang, L., Lodygin, D., et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J. Clin. Invest. 124 (2014), 1853–1867.
44. Blay, J.Y., Negrier, S., Combaret, V., Attali, S., Goillot, E., Merrouche, Y., et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 52 (1992), 3317–3322.
45. Hodge, D.R., Hurt, E.M., Farrar, W.L., The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer 41 (2005), 2502–2512.
46. Leibovich-Rivkin, T., Liubomirski, Y., Bernstein, B., Meshel, T., Ben-Baruch, A., Inflammatory factors of the tumor microenvironment induce plasticity in nontransformed breast epithelial cells: EMT, invasion, and collapse of normally organized breast textures. Neoplasia 15 (2013), 1330–1346.
47. Lv, N., Gao, Y., Guan, H., Wu, D., Ding, S., Teng, W., et al. Inflammatory mediators, tumor necrosis factor-alpha and interferon-gamma, induce EMT in human PTC cell lines. Oncol. Lett. 10 (2015), 2591–2597.
48. Singh, J.K., Simoes, B.M., Howell, S.J., Farnie, G., Clarke, R.B., Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res.: BCR, 15, 2013, 210.
49. Bendre, M.S., Gaddy-Kurten, D., Mon-Foote, T., Akel, N.S., Skinner, R.A., Nicholas, R.W., et al. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res. 62 (2002), 5571–5579.
50. Fernando, R.I., Castillo, M.D., Litzinger, M., Hamilton, D.H., Palena, C., IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res. 71 (2011), 5296–5306.
51. Stover, C., Dual role of complement in tumour growth and metastasis (Review). Int. J. Mol. Med. 25 (2010), 307–313.
52. Pio, R., Corrales, L., Lambris, J.D., The role of complement in tumor growth. Adv. Exp. Med. Biol. 772 (2014), 229–262.
53. Markiewski, M.M., Lambris, J.D., Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol. 30 (2009), 286–292.
54. Cho, M.S., Rupaimoole, R., Choi, H.J., Noh, K., Chen, J., Hu, Q., et al. Complement component 3 is regulated by TWIST1 and mediates epithelial-mesenchymal transition. J. Immunol. 196 (2016), 1412–1418.
55. Bulla, R., Tripodo, C., Rami, D., Ling, G.S., Agostinis, C., Guarnotta, C., et al. C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. Nat. Commun., 7, 2016, 10346.
56. Ohlund, D., Elyada, E., Tuveson, D., Fibroblast heterogeneity in the cancer wound. J. Exp. Med. 211 (2014), 1503–1523.
57. Ohlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A.S., Ponz-Sarvise, M., et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 214 (2017), 579–596.
58. Saadi, A., Shannon, N.B., Lao-Sirieix, P., O'Donovan, M., Walker, E., Clemons, N.J., et al. Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 2177–2182.
59. Shintani, Y., Fujiwara, A., Kimura, T., Kawamura, T., Funaki, S., Minami, M., et al. IL-6 secreted from cancer-associated fibroblasts mediates chemoresistance in NSCLC by increasing epithelial-mesenchymal transition signaling. J. Thorac. Oncol. 11 (2016), 1482–1492.
60. Del Pozo Martin, Y., Park, D., Ramachandran, A., Ombrato, L., Calvo, F., Chakravarty, P., et al. Mesenchymal cancer cell-stroma crosstalk promotes niche activation, epithelial reversion, and metastatic colonization. Cell Rep. 13 (2015), 2456–2469.
61. Lieubeau, B., Garrigue, L., Barbieux, I., Meflah, K., Gregoire, M., The role of transforming growth factor beta 1 in the fibroblastic reaction associated with rat colorectal tumor development. Cancer Res. 54 (1994), 6526–6532.
62. Alba-Castellon, L., Olivera-Salguero, R., Mestre-Farrera, A., Pena, R., Herrera, M., Bonilla, F., et al. Snail1-sependent activation of cancer-associated fibroblast controls epithelial tumor cell invasion and metastasis. Cancer Res. 76 (2016), 6205–6217.
63. Ronnov-Jessen, L., Petersen, O.W., Bissell, M.J., Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol. Rev. 76 (1996), 69–125.
64. Bonnans, C., Chou, J., Werb, Z., Remodelling the extracellular matrix in development and disease. Nat. Rev. Mol. Cell Biol. 15 (2014), 786–801.
65. Wei, S.C., Yang, J., Forcing through tumor metastasis: the interplay between tissue rigidity and epithelial-Mesenchymal transition. Trends Cell Biol. 26 (2016), 111–120.
66. Bissell, M.J., Hines, W.C., Why don't we get more cancer:A proposed role of the microenvironment in restraining cancer progression. Nat. Med. 17 (2011), 320–329.
67. Griggs, L.A., Hassan, N.T., Malik, R.S., Griffin, B.P., Martinez, B.A., Elmore, L.W., et al. Fibronectin fibrils regulate TGF-beta1-induced epithelial-mesenchymal transition. Matrix Biol.: J. Int. Soc. Matrix Biol., 2017.
68. O'Connor, J.W., Gomez, E.W., Biomechanics of TGFbeta-induced epithelial-mesenchymal transition: implications for fibrosis and cancer. Clin. Transl. Med., 3, 2014, 23.
69. Gilbert, P.M., Weaver, V.M., Cellular adaptation to biomechanical stress across length scales in tissue homeostasis and disease. Semin. Dev. Biol., 2016.
70. Paszek, M.J., Zahir, N., Johnson, K.R., Lakins, J.N., Rozenberg, G.I., Gefen, A., et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 8 (2005), 241–254.
71. Radisky, D.C., Levy, D.D., Littlepage, L.E., Liu, H., Nelson, C.M., Fata, J.E., et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436 (2005), 123–127.
72. Lee, K., Chen, Q.K., Lui, C., Cichon, M.A., Radisky, D.C., Nelson, C.M., Matrix compliance regulates Rac1b localization, NADPH oxidase assembly, and epithelial-mesenchymal transition. Mol. Biol. Cell 23 (2012), 4097–4108.
73. Wei, S.C., Fattet, L., Tsai, J.H., Guo, Y., Pai, V.H., Majeski, H.E., et al. Matrix stiffness drives epithelial-mesenchymal transition and tumour metastasis through a TWIST1-G3BP2 mechanotransduction pathway. Nat. Cell Biol. 17 (2015), 678–688.
74. Ungewiss, C., Rizvi, Z.H., Roybal, J.D., Peng, D.H., Gold, K.A., Shin, D.H., et al. The microRNA-200/Zeb1 axis regulates ECM-dependent beta1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL. Sci. Rep., 6, 2016, 18652.
75. Bracken, C.P., Li, X., Wright, J.A., Lawrence, D.M., Pillman, K.A., Salmanidis, M., et al. Genome-wide identification of miR-200 targets reveals a regulatory network controlling cell invasion. EMBO J. 33 (2014), 2040–2056.
76. Peng, D.H., Ungewiss, C., Tong, P., Byers, L.A., Wang, J., Canales, J.R., et al. ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis. Oncogene 36 (2017), 1925–1938.
77. Levental, K.R., Yu, H., Kass, L., Lakins, J.N., Egeblad, M., Erler, J.T., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139 (2009), 891–906.
78. Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., et al. Role of YAP/TAZ in mechanotransduction. Nature 474 (2011), 179–183.
79. Shao, D.D., Xue, W., Krall, E.B., Bhutkar, A., Piccioni, F., Wang, X., et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158 (2014), 171–184.
80. Lehmann, W., Mossmann, D., Kleemann, J., Mock, K., Meisinger, C., Brummer, T., et al. ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. Nat. Commun., 7, 2016, 10498.
81. Gilkes, D.M., Semenza, G.L., Wirtz, D., Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat. Rev. Cancer 14 (2014), 430–439.
82. Wilson, W.R., Hay, M.P., Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11 (2011), 393–410.
83. Cairns, R.A., Harris, I.S., Mak, T.W., Regulation of cancer cell metabolism. Nat. Rev. Cancer 11 (2011), 85–95.
84. Estrella, V., Chen, T., Lloyd, M., Wojtkowiak, J., Cornnell, H.H., Ibrahim-Hashim, A., et al. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 73 (2013), 1524–1535.
85. Martinez-Zaguilan, R., Seftor, E.A., Seftor, R.E., Chu, Y.W., Gillies, R.J., Hendrix, M.J., Acidic pH enhances the invasive behavior of human melanoma cells. Clin. Exp. Metastasis 14 (1996), 176–186.
86. Murakami, T., Shibuya, I., Ise, T., Chen, Z.S., Akiyama, S., Nakagawa, M., et al. Elevated expression of vacuolar proton pump genes and cellular pH in cisplatin resistance. Int. J. Cancer 93 (2001), 869–874.
87. Yang, M.H., Wu, M.Z., Chiou, S.H., Chen, P.M., Chang, S.Y., Liu, C.J., et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat. Cell Biol. 10 (2008), 295–305.
88. Mamlouk, S., Wielockx, B., Hypoxia-inducible factors as key regulators of tumor inflammation. Int. J. Cancer 132 (2013), 2721–2729.
89. Sceneay, J., Chow, M.T., Chen, A., Halse, H.M., Wong, C.S., Andrews, D.M., et al. Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res. 72 (2012), 3906–3911.
90. Ye, L.Y., Chen, W., Bai, X.L., Xu, X.Y., Zhang, Q., Xia, X.F., et al. Hypoxia-Induced epithelial-to-Mesenchymal transition in hepatocellular carcinoma induces an immunosuppressive tumor microenvironment to promote metastasis. Cancer Res. 76 (2016), 818–830.
91. Imai, T., Horiuchi, A., Wang, C., Oka, K., Ohira, S., Nikaido, T., et al. Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am. J. Pathol. 163 (2003), 1437–1447.
92. Copple, B.L., Hypoxia stimulates hepatocyte epithelial to mesenchymal transition by hypoxia-inducible factor and transforming growth factor-beta-dependent mechanisms. Liver Int. 30 (2010), 669–682.
93. Mak, P., Leav, I., Pursell, B., Bae, D., Yang, X., Taglienti, C.A., et al. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 17 (2010), 319–332.
94. Kim, H.J., Park, J.W., Cho, Y.S., Cho, C.H., Kim, J.S., Shin, H.W., et al. Pathogenic role of HIF-1alpha in prostate hyperplasia in the presence of chronic inflammation. Biochim. Biophys. Acta 1832 (2013), 183–194.
95. Wu, M.Z., Tsai, Y.P., Yang, M.H., Huang, C.H., Chang, S.Y., Chang, C.C., et al. Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition. Mol. Cell 43 (2011), 811–822.
96. Tafani, M., Sansone, L., Limana, F., Arcangeli, T., De Santis, E., Polese, M., et al. The interplay of reactive oxygen species, hypoxia, inflammation, and sirtuins in cancer initiation and progression. Oxid. Med. Cell. Longevity, 2016, 2016, 3907147.
97. Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J., Schreiber, R.D., Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3 (2002), 991–998.
98. Schreiber, R.D., Old, L.J., Smyth, M.J., Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331 (2011), 1565–1570.
99. Mittal, D., Gubin, M.M., Schreiber, R.D., Smyth, M.J., New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr. Opin. Immunol. 27 (2014), 16–25.
100. Knutson, K.L., Lu, H., Stone, B., Reiman, J.M., Behrens, M.D., Prosperi, C.M., et al. Immunoediting of cancers may lead to epithelial to mesenchymal transition. J. Immunol. 177 (2006), 1526–1533.
101. Santisteban, M., Reiman, J.M., Asiedu, M.K., Behrens, M.D., Nassar, A., Kalli, K.R., et al. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res. 69 (2009), 2887–2895.
102. Chen, L., Gibbons, D.L., Goswami, S., Cortez, M.A., Ahn, Y.H., Byers, L.A., et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat. Commun., 5, 2014, 5241.
103. Mak, M.P., Tong, P., Diao, L., Cardnell, R.J., Gibbons, D.L., William, W.N., Patient-Derived, et al. A., Pan-Cancer, E.M.T., Signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition. Clin. Cancer Res. 22 (2016), 609–620.
104. Lou, Y., Diao, L., Cuentas, E.R., Denning, W.L., Chen, L., Fan, Y.H., et al. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin. Cancer Res. 22 (2016), 3630–3642.
105. Swanton, C., Intratumor heterogeneity: evolution through space and time. Cancer Res. 72 (2012), 4875–4882.
106. Dean, M., Fojo, T., Bates, S., Tumour stem cells and drug resistance. Nat. Rev. Cancer 5 (2005), 275–284.
107. Visvader, J.E., Lindeman, G.J., Cancer stem cells: current status and evolving complexities. Cell Stem Cell 10 (2012), 717–728.
108. Manic, G., Signore, M., Sistigu, A., Russo, G., Corradi, F., Siteni, S., et al. CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. Gut, 2017.
109. Mani, S.A., Guo, W., Liao, M.J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 (2008), 704–715.
110. Chaffer, C.L., Marjanovic, N.D., Lee, T., Bell, G., Kleer, C.G., Reinhardt, F., et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 154 (2013), 61–74.
111. Oshimori, N., Oristian, D., Fuchs, E., TGF-beta promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell 160 (2015), 963–976.
112. Guo, W., Keckesova, Z., Donaher, J.L., Shibue, T., Tischler, V., Reinhardt, F., et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148 (2012), 1015–1028.
113. Luanpitpong, S., Li, J., Manke, A., Brundage, K., Ellis, E., McLaughlin, S.L., et al. SLUG is required for SOX9 stabilization and functions to promote cancer stem cells and metastasis in human lung carcinoma. Oncogene 35 (2016), 2824–2833.
114. Yang, M.H., Hsu, D.S., Wang, H.W., Wang, H.J., Lan, H.Y., Yang, W.H., et al. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat. Cell Biol. 12 (2010), 982–992.
115. Vermeulen, L., De Sousa, E.M.F., van der Heijden, M., Cameron, K., de Jong, J.H., Borovski, T., et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12 (2010), 468–476.
116. Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P.G., et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150 (2012), 165–178.
117. Li, J., Liu, H., Yu, J., Yu, H., Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor beta signaling in HCT116 colon cancer cells. Mol. Med. Rep. 12 (2015), 192–198.
118. Bruchard, M., Mignot, G., Derangere, V., Chalmin, F., Chevriaux, A., Vegran, F., et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat. Med. 19 (2013), 57–64.
119. Gomez-Casal, R., Bhattacharya, C., Ganesh, N., Bailey, L., Basse, P., Gibson, M., et al. Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes. Mol. Cancer, 12, 2013, 94.
120. Aguilera, T.A., Rafat, M., Castellini, L., Shehade, H., Kariolis, M.S., Hui, A.B., et al. Reprogramming the immunological microenvironment through radiation and targeting Axl. Nat. Commun., 7, 2016, 13898.
121. Zhang, Z., Lee, J.C., Lin, L., Olivas, V., Au, V., LaFramboise, T., et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 44 (2012), 852–860.
122. Rankin, E.B., Fuh, K.C., Castellini, L., Viswanathan, K., Finger, E.C., Diep, A.N., et al. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 13373–13378.
123. Aguilera, T.A., Giaccia, A.J., Molecular pathways oncologic pathways and their role in T-cell exclusion and immune evasion- a new role for the AXL receptor tyrosine kinase. Clin. Cancer Res., 2017.
124. Carbone, C., Moccia, T., Zhu, C., Paradiso, G., Budillon, A., Chiao, P.J., et al. Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. Clin. Cancer Res. 17 (2011), 5822–5832.
125. Shojaei, F., Ferrara, N., Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother. 11 (2008), 219–230.
126. Hugo, W., Zaretsky, J.M., Sun, L., Song, C., Moreno, B.H., Hu-Lieskovan, S., et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165 (2016), 35–44.
127. Boisgerault, N., Kottke, T., Pulido, J., Thompson, J., Diaz, R.M., Rommelfanger-Konkol, D., et al. Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse. Mol. Ther.: J. Am. Soc. Gene Ther. 21 (2013), 1507–1516.
128. Bhat, R., Bissell, M.J., Of plasticity and specificity: dialectics of the micro- and macro-environment and the organ phenotype. Wiley Interdiscip. Rev. Membr. Transp. Signal. 3 (2014), 147–163.